- Conditions
- Chronic Kidney Disease
- Interventions
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 72
- States / cities
- Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 7,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- etaracizumab, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
- Conditions
- Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
- Interventions
- Standard number of injection sites, Reduced number of injection sites
- Procedure
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- End Stage Renal Disease, Chronic Hepatitis c
- Interventions
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 34 Years to 44 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
- Interventions
- AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo
- Drug
- Lead sponsor
- Ardelyx
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota
- Conditions
- Acute Kidney Injury Following Cardiac Surgery
- Interventions
- TIN816, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 100 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Durham, North Carolina
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
- Interventions
- Phenazopyridine, 1% lidocaine with sodium bicarbonate
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Chronic Kidney Disease
- Interventions
- Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Hematuria, Urination Disorders, Voiding Dysfunction, Recurrent Urinary Tract Infection
- Interventions
- Flexible Cystoscopy, Rigid Cystoscopy
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
- Interventions
- zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- IC - Interstitial Cystitis
- Interventions
- Ferumoxytol, Gadobutrol
- Diagnostic Test
- Lead sponsor
- Christopher J Chermansky, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Phase 1b, HC-7366, SHARK, Kidney Cancer
- Interventions
- Nivolumab, HC-7366, ipilimumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • Atlanta, Georgia + 3 more
- Conditions
- Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
- Interventions
- Poly-L-Lactic Acid (Sculptra) injection, Placebo injection (sterile water)
- Device · Other
- Lead sponsor
- Cassandra Kisby
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Prostate Cancer, Kidney Cancer
- Interventions
- High intensity approach, Low intensity approach
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Chambersburg, Pennsylvania
- Conditions
- Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
- Interventions
- Sodium zirconium cyclosilicate, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 29
- States / cities
- Florence, Alabama • Chula Vista, California • Downey, California + 25 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Renal Insufficiency, Diabetes Mellitus
- Interventions
- Sodium bicarbonate, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- ARGX-121, Placebo
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • Pontiac, Michigan • Houston, Texas + 1 more
- Conditions
- Kidney Diseases
- Interventions
- Kidney Health Coaching, Usual Care
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more
- Conditions
- Kidney Stone
- Interventions
- Baking Soda, LithoLyte
- Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Stress Urinary Incontinence
- Interventions
- Intervention
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 1
- States / cities
- North Wales, Pennsylvania
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey